**
This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read TScan Therapeutics’s 8K filing here.
About TScan Therapeutics
TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.
Featured Stories
- Five stocks we like better than TScan Therapeutics
- 3 Healthcare Dividend Stocks to Buy
- Amazon’s Healthcare Gamble: A New Era of Medical Disruption
- 3 Tickers Leading a Meme Stock Revival
- Semiconductor Giant Synopsys Slides 14% — Time to Take Notice
- How to Invest in Tech Stocks and Top Tech Stocks to Consider
- Tesla’s Closes in on $400: From Laggard to Leader in 2024
